The Food and Drug Administration granted Fast Track designation to Fate Therapeutics Inc. (Nasdaq: FATE) for its ProTmune to reduce the incidence and severity of acute graft-versus-host disease. Shares of the biopharmaceutical climbed 49 cents to $2.17.
